Effects of Rivaroxaban on Vascular FMD in Patients With Stable Atherosclerotic Vascular Diseases

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 140 participants.

Also called NCT06986369

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 140 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06986369
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06986369. Randomized; double masking; primary purpose treatment. Start 2021-05-04 (actual); primary completion 2023-08-28 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effects of Rivaroxaban on Vascular FMD in Patients With Stable Atherosclerotic Vascular Diseases
Condition
Atherosclerosis, Coronary
Intervention (Drug)
Rivaroxaban 2.5 MG Oral Tablet [Xarelto]
Lead sponsor
The University of Hong Kong (class: other)
Collaborator
Bayer (class: industry)

Record details

Record id
cardio:ct-nct06986369
Content hash
078d0a1bd51194abbac8ad60ff81f698d9f54ae9f33e45719535e1866bbc3b90